Publications
Publications 1251 - 1275 de 33557
| Titre | DOI |
|---|---|
|
A quantum chemistry evaluation of the stereochemical activity of the lone pair in Pb-II complexes with sequestering ligands A. Moncomble; J.P. Cornard; M. Meyer 2017 |
10.1007/s00894-016-3190-y |
|
A quantum dynamics study of the benzopyran ring opening guided by laser pulses M. Saab; L.Joubert Doriol; B. Lasorne; S. Guerin; F. Gatti 2014 |
10.1016/j.chemphys.2014.01.016 |
|
A radiomic biomarker characterizing tumor dissemination in patients has complementary predictive value to metabolic tumor volume in a large cohort of diffuse large B-cell lymphoma patients responding to R-CHOP treatment A.Segolene Cottereau; M. Meignan; C. Nioche; J. Clerc; L. Vercellino; O. Casasnovas; C. Thieblemont; I. Buvat 2020 |
|
|
A radiomic biomarker characterizing tumor dissemination in patients has complementary predictive value to metabolic tumor volume in a large cohort of diffuse large B-cell lymphoma patients responding to R-CHOP treatment A.Segolene Cottereau; M. Meignan; C. Nioche; J. Clerc; L. Vercellino; O. Casasnovas; C. Thieblemont; I. Buvat 2020 |
|
|
A random forest approach for predicting the presence of Echinococcus multilocularis intermediate host Ochotona spp. presence in relation to landscape characteristics in western China C.G. Marston; M. Danson; R.P. Armitage; P. Giraudoux; D.R.J. Pleydell; Q. Wang; J. Qui; P.S. Craig 2014 |
10.1016/j.apgeog.2014.09.001 |
|
A random testing approach using pushdown automata A. Dreyfus; P.C. Heam; O. Kouchnarenko; C. Masson 2014 |
10.1002/stvr.1526 |
|
A randomised comparison of strategies for congenital toxoplasmosis retinochoroiditis prevention: included children F. Kieffer; M. Wallon; A. Bourredjem; A. Felin; P. Garcia-Meric; P. Dureau; I. Villena; J.B. Gouyon; T. Ginhoux; M. Saidi; V. Javerliac; C. Assouline; M. Kassis; V. Rouland; S. Couderc; E. Issert; P. Minodier; P. Quetin; H. Halep; N. Touil; C. Cornu; C. Binquet 2019 |
|
|
A randomised trial of the effects of prenatal education of overweight or obese pregnant women to prevent childhood overweight: the ETOIG study S. Parat; V. Negre; A. Baptiste; M.T. Tauber; P. Valensi; A.M. Bertrand; M. Dabbas; C. Elie; F. Lorenzini; E. Cosson 2015 |
|
|
A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study) M. Michel; L. Terriou; F. Roudot-Thoraval; M. Hamidou; M. Ebbo; G. Le Guenno; L. Galicier; S. Audia; B. Royer; A.S. Morin; J.Marie Michot; A. Jaccard; L. Frenzel; M. Khellaf; B. Godeau 2017 |
10.1002/ajh.24570 |
|
A randomized controlled double-blind clinical trial comparing versus placebo the effect of an edible algal extract (Ulva Lactuca) on the component of depression in healthy volunteers with anhedonia F.A. Allaert; H. Demais; P.Nyvall Collen 2018 |
10.1186/s12888-018-1784-x |
|
A randomized controlled study assessing outcome, cognition, autonomy and quality of life in over 70-year-old patients after aneurysmal subarachnoid hemorrhage F. Proust; S. Bracard; J.P. Lejeune; L. Thines; X. Leclerc; G. Penchet; J. Berge; X. Morandi; J.Y. Gauvrit; K. Mourier; F. Ricolfi; M. Lonjon; J. Sedat; B. Bataille; J. Droineau; T. Civit; E. Magro; I. Pelissou-Guyotat; H. Cebula; K. Lallouche; P. David; E. Emery; P. Courtheoux; J.R. Vignes; J. Benichou; N. Aghakani; P.H. Roche; E. Gay; P. Bessou; J. Guabrillargues; B. Irthum; F.A.S.H.E. Investigators 2018 |
10.1016/j.neuchi.2018.08.004 |
|
A Randomized Controlled Trial Comparing Crude Versus Heparin-Bonded PTFE Graft in Below the Knee Bypass Surgery for Critical Limb Ischemia (REPLACE Trial): Design and Protocol Y. Goueffic; J.P. Favre; E. Steinmetz; A. Ordureau; V.P. Riche; B. Guyomarch; E. Rosset 2019 |
10.1016/j.avsg.2018.11.016 |
|
A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment (EORT I. Ray-Coquard; H. Hatcher; E. Bompas; A. Casado; A. Westermann; N. Isambert; P.Giovanni Casali; S. Pratap; D. Stark; C. Valverde; A. Anand; M. Huizing; A. Floquet; L. Lindner; B. Hermes; B. Seddon; C. Coens; R. Jones; N. Reed 2020 |
10.1136/ijgc-2020-001519 |
|
A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing after first line therapy: EORTC 1209. M. Schlumberger; K. Newbold; B. Hasan; S. Marreaud; S. Assele; L.F. Licitra; P. Schoffski; S. Leboulleux; L. Locati; Y. Godbert; V. Rohmer; B. Jarzab; S. Domenico; O.Edgar Bechter; S. Zanetta; J. Capdevila; E. Kapiteijn; L. Bastholt 2018 |
10.1200/JCO.2018.36.15_suppl.6021 |
|
A randomized non-comparative phase II study of maintenance therapy with FOLFIRI alone or in combination with Tedopi vaccine after induction therapy with FOLFIRINOX in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (TEDOPAM-D M. Hilmi; V. Hautefeuille; A. Lambert; M.L.Garcia Larnicol; D. Vernerey; C. Neuzillet 2021 |
10.1016/j.annonc.2021.08.814 |
|
A randomized noncompartive phase II study of maintenance therapy with multiepitope vaccine Tedopi (OSE2101) +/- nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC) C. Neuzillet; V. Hautefeuille; A. Lambert; M.L. Garcia-Larnicol; D. Vernerey 2019 |
10.1200/JCO.2019.37.15_suppl.TPS4160 |
|
A Randomized Phase I Pharmacokinetic Study Comparing Biosimilar Candidate SB3 and Trastuzumab in Healthy Male Subjects X. Pivot; E. Curtit; Y.Jung Lee; G. Golor; A. Gauliard; D. Shin; Y. Kim; H. Kim; R. Fuhr 2016 |
10.1016/j.clinthera.2016.06.002 |
|
A randomized phase II study of maintenance therapy with multiepitope vaccine tedopi (OSE2101) +/- nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaM - PR C. Neuzillet; V. Hautefeuille; A. Lambert; M.L. Garcia-Larnicol; D. Vernerey 2019 |
|
|
A randomized phase II study of maintenance therapy with multiepitope vaccine tedopi (OSE2101) +/- nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaM - PR C. Neuzillet; V. Hautefeuille; A. Lambert; M.L. Garcia-Larnicol; D. Vernerey 2019 |
|
|
A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial J.B. Bachet; B. Chibaudel; F. Bonnetain; P. Validire; P. Hammel; T. Andre; C. Louvet; G.E.R.C.O.R. Grp 2015 |
10.1186/s12885-015-1656-4 |
|
A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma A.A. Brandes; M. Gil-Gil; F. Saran; A.F. Carpentier; A.K. Nowak; W. Mason; V. Zagonel; F. Dubois; G. Finocchiaro; G. Fountzilas; D.Michaela Cernea; O. Chinot; R. Anghel; F. Ghiringhelli; P. Beauchesne; G. Lombardi; E. Franceschi; M. Makrutzki; C. Mpofu; H.J. Urban; J. Pichler 2019 |
10.1634/theoncologist.2018-0290 |
|
A randomized phase II trial of azacitidine plus /- epoetin-beta in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents S. Thepot; R. Ben Abdelali; S. Chevret; A. Renneville; O. Beyne-Rauzy; T. Prebet; S. Park; A. Stamatoullas; A. Guerci-Bresler; S. Cheze; G. Tertian; B. Choufi; L. Legros; J.Noel Bastie; J. Delaunay; M.Pierre Chaury; L. Sanhes; E. Wattel; F. Dreyfus; N. Vey; F. Chermat; C. Preudhomme; P. Fenaux; C. Gardin; GFM 2016 |
10.3324/haematol.2015.140988 |
|
A randomized trial of 6-month norfloxacin therapy in patients with Child-Pugh class C cirrhosis R. Moreau; L. Elkrief; C. Bureau; J.M. Perarnau; T. Thevenot; F. Saliba; A. Louvet; P. Nahon; F. Oberti; R. Anty; S. Hillaire; B. Pasquet; V. Ozenne; M. Rudler; I. Ollivier-Hourmand; M.A. Robic; L. D'alteroche; V. Di Martino; P.E. Rautou; N. Gault; D. Lebrec 2017 |
10.1016/S0168-8278(17)30264-7 |
|
A Randomized, Controlled Trial of Oral Propranolol in Infantile Hemangioma C. Leaute-Labreze; P. Hoeger; J. Mazereeuw-Hautier; L. Guibaud; E. Baselga; G. Posiunas; R.J. Phillips; H. Caceres; J.C.Lopez Gutierrez; R. Ballona; S.F. Friedlander; J. Powell; D. Perek; B. Metz; S. Barbarot; A. Maruani; Z.Z. Szalai; A. Krol; O. Boccara; R. Foelster-Holst; M.I.Febrer Bosch; J. Su; H. Buckova; A. Torrelo; F. Cambazard; R. Grantzow; O. Wargon; D. Wyrzykowski; J. Roessler; J. Bernabeu-Wittel; A.M. Valencia; P. Przewratil; S. Glick; E. Pope; N. Birchall; L. Benjamin; A.J. Mancini; P. Vabres; P. Souteyrand; I.J. Frieden; C.I. Berul; C.R. Mehta; S. Prey; F. Boralevi; C.C. Morgan; S. Heritier; A. Delarue; J.J. Voisard 2015 |
10.1056/NEJMoa1404710 |
|
A randomized, double-blind, phase III study comparing SB3 (trastuzumab biosimilar) with originator trastuzumab in patients treated by neoadjuvant therapy for HER2-positive early breast cancer X.B. Pivot; I. Bondarenko; M. Dvorkin; E. Trishkina; J.H. Ahn; S.A. Im; T. Sarosiek; S. Chattopadhyay; M. Wojtukiewicz; V. Moiseyenko; Y.V. Shparyk; M.De Guzman Bello; V. Semiglazov; S. Song; J.Yun Lim 2017 |
10.1200/JCO.2017.35.15_suppl.509 |